openPR Logo
Press release

Primary Biliary Cholangitis Therapeutics Market: Current Status and Future Prospects

07-25-2023 10:51 AM CET | Health & Medicine

Press release from: Allied Market Research

Primary Biliary Cholangitis Therapeutics Market: Current

The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

CAGR: 7.1%
Current Market Size: USD 1.4 Billion
Fastest Growing Region: APAC
Largest Market: North America
Projection Time: 2023-2032
Base Year: 2022

Primary Biliary Cholangitis (PBC), formerly known as Primary Biliary Cirrhosis, is a chronic liver disease characterized by the inflammation and destruction of small bile ducts in the liver. Over time, this condition can lead to liver damage, cirrhosis, and complications. The management of PBC has significantly evolved in recent years, with the development of targeted therapies and promising treatment options. In this blog, we will explore the current status of the PBC therapeutics market and its potential future prospects.

๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž - https://www.alliedmarketresearch.com/request-sample/109023

๐“๐ก๐ž ๐‚๐ฎ๐ซ๐ซ๐ž๐ง๐ญ ๐‹๐š๐ง๐๐ฌ๐œ๐š๐ฉ๐ž ๐จ๐Ÿ ๐๐๐‚ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ
Traditionally, the treatment for PBC has involved the use of ursodeoxycholic acid (UDCA), which is effective for many patients, particularly in the early stages of the disease. UDCA helps to improve liver function and slow down disease progression. However, a subset of patients may not respond adequately to UDCA or may experience disease progression despite treatment.

In recent years, research and clinical trials have focused on the development of new therapeutic options for PBC patients, especially those who do not respond to or tolerate UDCA. The emergence of novel drugs targeting specific mechanisms of the disease has been a game-changer for PBC management.

๐“๐š๐ซ๐ ๐ž๐ญ๐ž๐ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ข๐ž๐ฌ ๐ข๐ง ๐๐๐‚
One of the most significant breakthroughs in PBC therapeutics has been the approval of obeticholic acid (OCA). OCA is a potent farnesoid X receptor (FXR) agonist that helps regulate bile acid synthesis and transport. Clinical trials have demonstrated its efficacy in improving liver function, reducing alkaline phosphatase levels, and slowing down the progression of fibrosis in PBC patients.

In addition to OCA, there are ongoing studies investigating other FXR agonists and combination therapies to further optimize treatment outcomes for PBC patients.

๐๐ซ๐จ๐œ๐ฎ๐ซ๐ž ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ญ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ (229 ๐๐š๐ ๐ž๐ฌ ๐๐ƒ๐… ๐ฐ๐ข๐ญ๐ก ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐‚๐ก๐š๐ซ๐ญ๐ฌ, ๐“๐š๐›๐ฅ๐ž๐ฌ, ๐š๐ง๐ ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ) @ https://www.alliedmarketresearch.com/primary-biliary-cholangitis-pbc-therapeutics-market/purchase-options

๐„๐ฆ๐ž๐ซ๐ ๐ข๐ง๐  ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐จ๐ฆ๐จ๐๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐€๐ ๐ž๐ง๐ญ๐ฌ
PBC is considered an autoimmune disease, and researchers have been exploring immunomodulatory agents to target the immune system's aberrant response. Trials are underway to evaluate the efficacy and safety of drugs such as bezlotoxumab, norursodeoxycholic acid (norUDCA), and mycophenolate mofetil in PBC management.

๐๐ž๐ซ๐ฌ๐จ๐ง๐š๐ฅ๐ข๐ณ๐ž๐ ๐Œ๐ž๐๐ข๐œ๐ข๐ง๐ž ๐ข๐ง ๐๐๐‚
As our understanding of the genetic and molecular factors influencing PBC grows, personalized medicine approaches are becoming more feasible. Biomarker-based diagnostic and treatment strategies hold the promise of tailoring therapies to individual patients, potentially improving treatment response rates and minimizing adverse effects.

๐“๐ก๐ž ๐…๐ฎ๐ญ๐ฎ๐ซ๐ž ๐จ๐Ÿ ๐๐๐‚ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ
Looking ahead, the PBC therapeutics market is poised for significant expansion. With the continuous exploration of novel drug targets, the pipeline of potential treatments is growing, offering hope for improved patient outcomes.

๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ž ๐˜๐จ๐ฎ๐ซ ๐„๐ฏ๐ž๐ซ๐ฒ ๐ƒ๐จ๐ฎ๐›๐ญ ๐‡๐ž๐ซ๐ž: https://www.alliedmarketresearch.com/purchase-enquiry/109023

Gene therapies, while still in the early stages of development, hold the potential to address the underlying genetic defects responsible for PBC. As research in this area advances, gene therapies could transform the landscape of PBC treatment in the future.

Furthermore, ongoing research may lead to the identification of new therapeutic targets, innovative drug delivery methods, and combination therapies that can further enhance treatment efficacy and patient quality of life.

๐Š๐ง๐จ๐ฐ ๐Œ๐จ๐ซ๐ž-https://www.alliedmarketresearch.com/primary-biliary-cholangitis-pbc-therapeutics-market-A108539

๐Ž๐ญ๐ก๐ž๐ซ ๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž ๐ƒ๐จ๐ฆ๐š๐ข๐ง
๐ฏ๐ข๐ซ๐š๐ฅ ๐ฏ๐ž๐œ๐ญ๐จ๐ซ ๐ฉ๐ซ๐จ๐๐ฎ๐œ๐ญ๐ข๐จ๐ง ๐Œ๐š๐ซ๐ค๐ž๐ญ https://www.alliedmarketresearch.com/viral-vector-production-market-A13615

๐๐ฅ๐š๐ฌ๐ฆ๐š ๐๐ซ๐จ๐ญ๐ž๐ข๐ง ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ https://www.alliedmarketresearch.com/plasma-protein-therapeutics-market-A12692

๐†๐š๐ฌ๐ญ๐ซ๐ข๐œ ๐‚๐š๐ง๐œ๐ž๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ https://www.alliedmarketresearch.com/gastric-cancer-market-A74458

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis Therapeutics Market: Current Status and Future Prospects here

News-ID: 3144641 • Views: โ€ฆ

More Releases from Allied Market Research

Converting Paper Market Poised for Remarkable Growth, to Surpass USD 545.9 Billion by 2033
Converting Paper Market Poised for Remarkable Growth, to Surpass USD 545.9 Billi โ€ฆ
The global converting paper market was valued at $341.9 billion in 2023 and is projected to reach $545.9 billion by 2033, growing at a CAGR of 4.8% from 2024 to 2033. This growth is fueled by the increasing demand for customized paper products across various industries, including packaging, publishing, and e-commerce. Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A10550 Converting paper refers to the process of transforming raw paperโ€ฆ
[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR
[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR
Trichlorosilane (SiHCl3) is a silicon-based chemical compound with the molecular formula SiHCl3. It is a key intermediate in the production of silicon-based materials and is primarily used to manufacture polysilicon, which is the main component in solar cells and semiconductor devices. TCS is produced by the hydrochlorination of silicon tetrachloride (SiCl4) or by the reaction of silicon with hydrogen chloride. The global trichlorosilane market size was valued at $5.4 billionโ€ฆ
Insights into the Gallic Acid Market Growth, Global Industry Forecast, 2033
Insights into the Gallic Acid Market Growth, Global Industry Forecast, 2033
Gallic acid (C7H6O5), also known as 3,4,5-trihydroxybenzoic acid, is a naturally occurring phenolic acid found in many plants, fruits, and natural substances like tea, grapes, berries, and oak bark. It is a secondary plant metabolite that plays a key role in plant defense mechanisms. The global gallic acid market was valued at $81.0 million in 2023, and is projected to reach $137.5 million by 2033, growing at a CAGR ofโ€ฆ
[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opportunities, 2033
[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opp โ€ฆ
A single crystal diamond is a diamond with a continuous and uninterrupted crystal lattice structure, free of grain boundaries or polycrystalline defects. Unlike polycrystalline diamonds, which have multiple small crystals fused together, single crystal diamonds have a perfect, uniform atomic arrangement. The global single crystal diamond market was valued at $1.5 billion in 2023, and is projected to reach $2.4 billion by 2033, growing at a CAGR of 4.7% fromโ€ฆ

All 5 Releases


More Releases for PBC

Crowdfunding Market Is Going to Boom Rapidly | Kickstarter PBC, Indiegogo Inc., โ€ฆ
Coherent Market Insights has added a new research study on the Global "Crowdfunding Market" 2026 by Size, Growth, Trends, and Dynamics, Forecast to 2033 which is a result of an extensive examination of the market patterns. This report covers a comprehensive investigation of the information that influences the market regarding fabricates, business providers, market players, and clients. The report provides data about the aspects which drive the expansion of theโ€ฆ
Primary Biliary Cirrhosis (PBC) Market Emerging Trends and Growth Prospects 2034
Introduction Primary Biliary Cirrhosis (PBC), now often referred to as Primary Biliary Cholangitis, is a chronic autoimmune liver disease that slowly destroys bile ducts, leading to bile buildup, liver scarring, and eventual cirrhosis. It predominantly affects middle-aged women and is often associated with fatigue, itching, and complications that can severely impair quality of life. With rising autoimmune disease prevalence, improved screening, and a growing focus on rare liver disorders, the global marketโ€ฆ
Primary Biliary Cholangitis (PBC) Market Trends, Challenges and Growth Forecast
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that progressively destroys intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and eventually liver failure. The condition predominantly affects middle-aged women and is often associated with fatigue, pruritus, and elevated liver enzymes. Without effective management, PBC can result in severe complications, including portal hypertension, hepatocellular carcinoma (HCC), and the need for liver transplantation. The PBC market has historically relied on ursodeoxycholicโ€ฆ
Plain Bearing Market Is Booming Worldwide |PBC Linear, Timken Company, THK
Advance Market Analytics published a new research publication on "Plain Bearing Market Insights, to 2030" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Plain Bearing market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy ofโ€ฆ
Primary Biliary Cholangitis (PBC) Treatment Market Outlook 2016 To 2024 โ€“ Glob โ€ฆ
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causesโ€ฆ
Primary Biliary Cholangitis (PBC) Treatment Market : Analysis And Forecast (2016 โ€ฆ
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causesโ€ฆ